Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Dr Eoghan Mulholland has received the prestigious Lee Placito Research Fellowship in Gastrointestinal Cancer. Eoghan will use this 3-year position to research cell interactions in colorectal cancers.

Eoghan Muholland

Dr Eoghan Mulholland, Postdoctoral Research Scientist in Cancer Genetics at the Wellcome Centre for Human Genetics and member of Somerville College has recently been awarded the Lee Placito Research Fellowship in Gastrointestinal Cancer.

Colorectal cancer (CRC) is currently the 2nd most common cause of cancer death in the UK. To date, research tells us that it isn’t just the genetic defects in the cancer cells that influences how a cancer behaves, but also how the supporting (stromal) and immune cells interact with it. Currently we don’t fully understand how these ‘cell conversations’ initiate and develop but using cutting-edge research methodologies we can have the opportunity to ‘eavesdrop’. Using the Lee Placito Fellowship, Dr Mulholland  will focus in on these cellular exchanges to better understand how cancer cells, stromal cells and immune cells interact with each other across both human tissue and in Genetically Engineered Mouse Models. Through better understanding of this we can then hope to influence how the cells conversation, change the CRC dynamics, and ultimately improve treatment.

On receiving this Fellowship, Dr Mulholland commented:Using the Lee Placito Fellowship, I will focus in on the ‘cell conversations’ between cancer cells, stromal cells and immune cells. Through better understanding of this we can then hope to influence how the cells communicate, change the colorectal cancer dynamics, and ultimately improve treatment.’

Find out more about the Lee Placito Research Fellowship

Similar stories

Com-COV vaccine study to research third dose booster options for 12-to-15-year-olds

Researchers running the University of Oxford-led Com-COV programme have launched a further study of COVID-19 vaccination schedules in young people aged 12 to 15 – with a focus on assessing different options for a third dose booster vaccination.

Population-scale study highlights ongoing risk of COVID-19 in some cancer patients despite vaccination

COVID-19 vaccination is effective in most cancer patients, but the level of protection against COVID-19 infection, hospitalisation and death offered by the vaccine is less than in the general population and vaccine effectiveness wanes more quickly.

New reporting guidelines developed to improve AI in healthcare settings

New reporting guidelines, jointly published in Nature Medicine and the BMJ by Oxford researchers, will ensure that early studies on using Artificial Intelligence (AI) to treat real patients will give researchers the information needed to develop AI systems safely and effectively.

Major boost for Oxford’s mission to counter future pandemic threats

The Moh Family Foundation has given a substantial gift to support the work of Oxford University’s Pandemic Sciences Institute, greatly strengthening its ability to identify and counter future pandemic threats and ensure equitable access to treatments and vaccines around the world.

Three NHSBT research units launch at University of Oxford

The NIHR has awarded three new Blood and Transplant Research Units (BTRUs) to the University of Oxford.